BioNTech’s shares soared on Friday after the company sought approval from European regulators. Pfizer (((PFE)-Affiliated Covid vaccine for teens.
If permitted, people aged 12 to 15 are eligible to receive the coronavirus vaccine in all 27 member states of the European Union. BioNTech (((BNTX) And Pfizer have already requested similar changes to approval in the United States
The submission is based on a final stage study of 2,260 participants aged 12 to 15 years. The vaccine has proven to be 100% effective for teens, whether or not they have been previously infected with Covid. Researchers will monitor participants for 2 years after the second dose.
To Stock market today, BioNTech’s share price rose 4.8% to 188.28. Pfizer stock The fraction has increased to 38.65. As a leading pharmaceutical company with a large number of approved drugs, Pfizer’s share does not fluctuate much in the Covid vaccine news.
BioNTech’s share price soars in response to European demand
Pfizer and BioNTech’s Covid vaccine has already been approved in the United States, Europe, and various countries for adults over the age of 18. Two-injection vaccines use messenger RNA, a new technology that leverages the body’s mechanisms to build proteins.
The virus that causes Covid is covered with so-called spike proteins. Pfizer and BioNTech vaccines direct the body to make a single pepomer. It stimulates an immune response. Modana (((MRNA) Make a vaccine using the same technology.
The BioNTech strain has soared from a relatively ambiguous state due to the promise of Covid vaccine and messenger RNA technology. When it went public in October 2019, the stock traded just over 12. Currently, BioNTech shares are traded at approximately 188.
On a year-to-date basis, BioNTech’s inventory surged 131%.
Follow Allison Gatlin on Twitter. @IBD_AGatlin..
You may like it too:
BioNTech Stock is expanding its breakout as it seeks to expand its Covid vaccine to teens
Source link BioNTech Stock is expanding its breakout as it seeks to expand its Covid vaccine to teens